Annals of Tropical Medicine and Public Health
Home About us Ahead Of Print Instructions Submission Subscribe Advertise Contact e-Alerts Editorial Board Login 
Users Online:909
  Print this page  Email this page Small font sizeDefault font sizeIncrease font size
 


 
Table of Contents   
LETTER TO THE EDITOR  
Year : 2016  |  Volume : 9  |  Issue : 3  |  Page : 197
Immunomodulatory adjunctive treatment options for Ebola virus disease: Possibility and how?


Hainan Medical University, Haikou, Hainan, China; Joseph Ayobabalola University, Nigeria

Click here for correspondence address and email

Date of Web Publication3-May-2016
 

How to cite this article:
Wiwanitkit V. Immunomodulatory adjunctive treatment options for Ebola virus disease: Possibility and how?. Ann Trop Med Public Health 2016;9:197

How to cite this URL:
Wiwanitkit V. Immunomodulatory adjunctive treatment options for Ebola virus disease: Possibility and how?. Ann Trop Med Public Health [serial online] 2016 [cited 2019 Dec 12];9:197. Available from: http://www.atmph.org/text.asp?2016/9/3/197/181662
Dear Sir,

Ebola virus disease is the present concern in public health. Finding effective new therapeutic technique is the urgent requirement. The recent report on “immunomodulatory adjunctive treatment options for Ebola virus disease” is very interesting.[1] In fact, in the present day, the immunomodulation technique becomes a new alternative way for management of several infectious diseases. For the Ebola virus disease, there is still no conclusion on the effective management. The management is generally supportive, similar to any other hemorrhagic viral diseases.[2] To use immunomodulatory adjunctive treatment, there are two big questions. First, the possibility of the technique should be discussed. Although there are many drugs (such as statins) that are mentioned for the ability to modify the host report that might be useful for management of the infection. The question that remains is the unclear immunopathogenesis of the Ebola virus disease and the unclear pharmacological reaction of those drugs.[3] The big consideration, based on the mentioned unclear issues, is the lack for knowledge on how to dose the immunomodulative drugs. Too much or too little immune-modification might be problematic and this might result in unwanted reaction. Second, how to perform this kind of therapy should also be discussed. With the lack of data, it is very hard to decide when to start the treatment, and what is the best period for applying such treatment. These issues remain as interesting aspect for further researches on Ebola virus disease.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

 
   References Top

1.
Fedson DS. Immunomodulatory adjunctive treatment options for Ebola virus disease patients: Another view. Intensive Care Med 2015;41:1383.  Back to cited text no. 1
    
2.
Wiwanitkit V. Ebola virus infection: What should be known? N Am J Med Sci 2014;6:549-52.   Back to cited text no. 2
    
3.
Kilgore PE, Grabenstein JD, Salim AM, Rybak M. Treatment of ebola virus disease. Pharmacotherapy 2015;35:43-53.  Back to cited text no. 3
    

Top
Correspondence Address:
Viroj Wiwanitkit
Hainan Medical University, Haikou, Hainan, China; Joseph Ayobabalola University, Nigeria

Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/1755-6783.181662

Rights and Permissions




 

Top
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Email Alert *
    Add to My List *


    References

 Article Access Statistics
    Viewed937    
    Printed19    
    Emailed0    
    PDF Downloaded29    
    Comments [Add]    

Recommend this journal